Targeting Breast Cancer Signaling via Phytomedicine and Nanomedicine
© 2023 S. Karger AG, Basel..
BACKGROUND: The development of breast cancer (BC) and how it responds to treatment have both been linked to the involvement of inflammation. Chronic inflammation is critical in carcinogenesis, leading to elevated DNA damage, impaired DNA repair machinery, cell growth, apoptosis, angiogenesis, and invasion. Studies have found several targets that selectively modulate inflammation in cancer, limit BC's growth, and boost treatment effectiveness. Drug resistance and the absence of efficient therapeutics for metastatic and triple-negative BC contribute to the poor outlook of BC patients.
SUMMARY: To treat BC, small-molecule inhibitors, phytomedicines, and nanoparticles are conjugated to attenuate BC signaling pathways. Due to their numerous target mechanisms and strong safety records, phytomedicines and nanomedicines have received much attention in studies examining their prospects as anti-BC agents by such unfulfilled demands.
KEY MESSAGES: The processes involved in the affiliation across the progression of tumors and the spread of inflammation are highlighted in this review. Furthermore, we included many drugs now undergoing clinical trials that target cancer-mediated inflammatory pathways, cutting-edge nanotechnology-derived delivery systems, and a variety of phytomedicines that presently address BC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
Pharmacology - 108(2023), 6 vom: 17., Seite 504-520 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ansari, Jeba Ajgar [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 23.11.2023 Date Revised 12.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000531802 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362448337 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362448337 | ||
| 003 | DE-627 | ||
| 005 | 20240412232512.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000531802 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM362448337 | ||
| 035 | |a (NLM)37748454 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ansari, Jeba Ajgar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeting Breast Cancer Signaling via Phytomedicine and Nanomedicine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.11.2023 | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 S. Karger AG, Basel. | ||
| 520 | |a BACKGROUND: The development of breast cancer (BC) and how it responds to treatment have both been linked to the involvement of inflammation. Chronic inflammation is critical in carcinogenesis, leading to elevated DNA damage, impaired DNA repair machinery, cell growth, apoptosis, angiogenesis, and invasion. Studies have found several targets that selectively modulate inflammation in cancer, limit BC's growth, and boost treatment effectiveness. Drug resistance and the absence of efficient therapeutics for metastatic and triple-negative BC contribute to the poor outlook of BC patients | ||
| 520 | |a SUMMARY: To treat BC, small-molecule inhibitors, phytomedicines, and nanoparticles are conjugated to attenuate BC signaling pathways. Due to their numerous target mechanisms and strong safety records, phytomedicines and nanomedicines have received much attention in studies examining their prospects as anti-BC agents by such unfulfilled demands | ||
| 520 | |a KEY MESSAGES: The processes involved in the affiliation across the progression of tumors and the spread of inflammation are highlighted in this review. Furthermore, we included many drugs now undergoing clinical trials that target cancer-mediated inflammatory pathways, cutting-edge nanotechnology-derived delivery systems, and a variety of phytomedicines that presently address BC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Cancer therapy | |
| 650 | 4 | |a Nanomedicines | |
| 650 | 4 | |a Natural products | |
| 650 | 4 | |a Phytomedicines | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Malik, Jonaid Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Sakeel |e verfasserin |4 aut | |
| 700 | 1 | |a Bhat, Faisal Ashraf |e verfasserin |4 aut | |
| 700 | 1 | |a Khanam, Afreen |e verfasserin |4 aut | |
| 700 | 1 | |a Mir, Suhail Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Abouzied, Amr S |e verfasserin |4 aut | |
| 700 | 1 | |a Ahemad, Nafees |e verfasserin |4 aut | |
| 700 | 1 | |a Anwar, Sirajudheen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacology |d 1968 |g 108(2023), 6 vom: 17., Seite 504-520 |w (DE-627)NLM000022705 |x 1423-0313 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2023 |g number:6 |g day:17 |g pages:504-520 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000531802 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2023 |e 6 |b 17 |h 504-520 | ||